[PDF][PDF] Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib (GDC‐0853) in systemic lupus erythematosus: results of a …

…, J Rae, O Hwang, R Desai, A Lokku… - Arthritis & …, 2021 - Wiley Online Library
Objective Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of
Bruton's tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib …

Cancer survivorship and opioid prescribing rates: a population‐based matched cohort study among individuals with and without a history of cancer

R Sutradhar, A Lokku, L Barbera - Cancer, 2017 - Wiley Online Library
BACKGROUND Little is known about opioid prescribing among individuals who have
survived cancer. Our aim is to examine a predominantly socio‐economically disadvantaged …

Trends and outcomes of patent ductus arteriosus treatment in very preterm infants in Canada

A Lokku, L Mirea, SK Lee, PS Shah… - American journal of …, 2017 - thieme-connect.com
Objective To assess trends in patent ductus arteriosus (PDA) management and examine
concurrent changes in neonatal mortality and morbidities. Methods This retrospective …

[HTML][HTML] Summarizing the extent of visit irregularity in longitudinal data

A Lokku, LS Lim, CS Birken, EM Pullenayegum… - BMC Medical Research …, 2020 - Springer
Background Observational longitudinal data often feature irregular, informative visit times.
We propose descriptive measures to quantify the extent of irregularity to select an …

Trends in unintentional injury mortality in Canadian children 1950–2009 and association with selected population-level interventions

SA Richmond, J D'Cruz, A Lokku… - Canadian journal of …, 2016 - Springer
OBJECTIVES: To examine unintentional injury mortality rates in children (0–19 years) in
Canada from 1950 to 2009 against national population-level injury prevention interventions …

Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials

LSH Lim, A Lokku, E Pullenayegum… - Arthritis Care & …, 2023 - Wiley Online Library
Objectives Most juvenile idiopathic arthritis (JIA) biologic disease‐modifying antirheumatic
drugs (bDMARDs) trials used an open‐label run‐in period followed by randomized …

OP0233 efficacy, safety, and pharmacodynamic effects of the bruton's tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus …

…, C Lee, A Mcgregor, B Toth, J Rae, O Hwang, A Lokku… - 2020 - ard.bmj.com
Background: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and selective inhibitor
of Bruton's tyrosine kinase (BTK) in clinical development for autoimmune diseases …

[HTML][HTML] Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials

LSH Lim, S Shobhan, A Lokku, S Ringold… - Pediatric …, 2022 - Springer
Aims 1) To delineate latent classes of treatment response to biologics in juvenile idiopathic
arthritis (JIA) patients in the first 16 weeks after initiation. 2) To identify predictors of early …

[BOOK][B] Summary Measures for Quantifying the Extent of Visit Irregularity in Longitudinal Data

A Lokku - 2020 - search.proquest.com
A common feature of observational longitudinal data is variability in the timings of visits
across individuals. Irregular visits merit careful scrutiny as they can be associated with the …

Quantifying the extent of visit irregularity in longitudinal data

A Lokku, CS Birken, JL Maguire… - … International Journal of …, 2022 - degruyter.com
The timings of visits in observational longitudinal data may depend on the study outcome,
and this can result in bias if ignored. Assessing the extent of visit irregularity is important …